ArticleChemical science2023
Acceptor engineering of metallacycles with high phototoxicity indices for safe and effective photodynamic therapy.
Article in Chemical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Counterion modulation of aza-BODIPY aggregation behaviour for boosted sonodynamic therapy.Chemical science · 2026Article
- Architecting NIR-II metal supramolecular dyes-illuminating the path to precision medicine.Chemical science · 2026Review
- Targeted Delivery of Schisandrin A to Cardiac Endothelium Alleviates Myocardial Ischemia-Reperfusion Injury via Suppression of Ferroptosis.International journal of nanomedicine · 2026Article
- Article
- Novel metallo-supramolecular architectures based on side-pyridine-modified terpyridines: design, self-assembly, and properties.Chemical science · 2025Review
- "Dual lock-and-key" triggered and endoplasmic reticulum targeting nanophotosensitizers for activatable Type-I photodynamic and photothermal therapies.Chemical science · 2025Article
- Size-tuned PEGylated NIR-II fluorescent probes for high-contrast plant imaging and TMV detection.Journal of nanobiotechnology · 2025Article
- Precision Imaging of Biothiols in Live Cells and Treatment Evaluation during the Development of Liver Injury via a Near-Infrared Fluorescent Probe.Chemical & biomedical imaging · 2025Article
- Engineering Stimuli-Responsive Materials for Precision Medicine.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Illuminating Hope for Tumors: The Progress of Light-Activated Nanomaterials in Skin Cancer.International journal of nanomedicine · 2025Review
- Cucurbit[8]uril Confinement-Based Secondary Coassembly for High-Efficiency Phosphorescence Energy Transfer Behavior.JACS Au · 2024Article
- Targeted Delivery and ROS-Responsive Release of Lutein Nanoassemblies Inhibit Myocardial Ischemia-Reperfusion Injury by Improving Mitochondrial Function.International journal of nanomedicine · 2024Article
- Enzyme-Instructed Aggregation/Dispersion of Fluorophores for Near-Infrared Fluorescence Imaging In Vivo.Molecules (Basel, Switzerland) · 2023Review
- Molecular Design of NIR-II Polymethine Fluorophores for Bioimaging and Biosensing.Chemical & biomedical imaging · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Although metallacycle-based photosensitizers have attracted increasing attention in biomedicine, their clinical application has been hindered by their inherent dark toxicity and unsatisfactory phototherapeutic efficiency. Herein, we employ a π-expansion strategy for ruthenium acceptors to develop a series of Ru(ii) metallacycles (Ru1-Ru4), while simultaneously reducing dark toxicity and enhancing phototoxicity, thus obtaining a high phototoxicity index (PI). These metallacycles enable deep-tissue (∼7 mm) fluorescence imaging and reactive oxygen species (ROS) production and exhibit remarkable anti-tumor activity even under hypoxic conditions. Notably, Ru4 has the lowest dark toxicity, highest ROS generation ability and an optimal PI (∼146). Theoretical calculations verify that Ru4 exhibits the largest steric bulk and the lowest singlet-triplet energy gap (Δ
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.